Creatine Phase III Clinical Trials For Parkinson’s Disease
(Best Syndication) Creatine has been used by body builders for years as a supplement to help build muscle mass, but recently there has been interest in it as a treatment for Parkinson’s disease. The phase III of the study will try to determine if creatine will slow the progression of the disease.
Doctor Elias A Zerhouni said “This study is an important step. We are pleased to have so many sites participating in this study, which may help us move more quickly toward developing a therapy that could change the course of this devastating disease.” Zerhouni is director of the National Institutes of Health (NIH).
“The goal is to improve the quality of life for people with Parkinson's for a longer period of time than is possible with existing therapies,” says Zerhouni. So far no treatment has been shown to slow the progression of Parkinson’s disease.
This double-blind, placebo-controlled, Phase III study is one of the largest Parkinson’s clinical trials to date. The Vanderbilt University Medical Center (VUMC) is one of 51 medical centers in the United States and Canada that will be recruiting patients. They are looking for 1,720 people with early-stage Parkinson’s. Neither the participants nor their doctors will know which patient will receive the placebo and which the Creatine.
“This study is an example of our commitment to Parkinson’s research,” said Story C. Landis, Ph.D., director of the National Institute of Neurological Disorders and Stroke (NINDS), the NIH institute leading the study. “We are trying to explore every possible option for reducing the burden of this disease.”
“This study represents the next major step in the quest for a medicine that can slow down the progression of Parkinson’s disease,” John Fang, M.D. said. “Earlier studies have shown promising results, but without a long-term study, we cannot know for sure.” Fang is the primary investigator at VUMC, of the Neurology department.
The study will enroll people who have been diagnosed with Parkinson’s within the past five years and who have been treated for two years or less with levodopa or other drugs that increase the levels of dopamine in the brain. Dopamine is a neurotransmitter that helps to control movement. Many of the symptoms of Parkinson’s disease result from the loss of dopamine. Half of the participants will receive creatine and half will receive a placebo.
The investigators will measure disease progression using standard rating scales that measure quality of life, ability to walk, cognitive function, and the ability to carry out other activities of daily living.
People interested in participating in this study can obtain more information by calling (800) 352-9424, e-mailing email@example.com, or visiting http://www.parkinsontrial.org/ to see a list of study sites (also attached).
By Marsha Quinn
Best Syndicaiton Health Writer